Início › Transtorno Depressivo Maior › Ohio
Ensaios clínicos de Transtorno Depressivo Maior em Ohio
29 estudos para Transtorno Depressivo Maior estão buscando participantes em locais em Ohio.
Cidades em Ohio
Texto oficial do estudo (Inglês)
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Patient Priority Clinical Sites LLC, Cincinnati
- The Ohio State University, Columbus
RecrutandoFase 3
Idades de 18 a 74 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06559306A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Cincinnati, Cincinnati
RecrutandoFase 3
Idades de 12 a 17 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07227454Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Quest Therapeutics of Avon Lake, Avon Lake
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
RecrutandoFase 3
Idades de 18 a 65 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05850689Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Cincinnati
RecrutandoFase 3
Idades de 18 a 65 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Independence
- Seaport Investigator Site, North Canton
RecrutandoFase 2
Idades de 18 a 65 · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Neuro-Behavioral Clinical Research, North Canton
RecrutandoFase 2
Idades de 18 a 65 · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Insight Clinical Trials, Independence
RecrutandoFase 3
Idades de 18 a 74 · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Columbus
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
Recrutando
Idades de 22 a 70 · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT06423430A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Patient Priority Clinical Sites LLC, Cincinnati
RecrutandoFase 3
Idades de 18 a 74 · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07573176Positive Processes and Transition to Health (PATH)
- Case Western Reserve University, Cleveland
Recrutando
Idades de 18 a 65 · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06093906NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mason
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Cleveland Clinic, Cleveland
RecrutandoFase 3
Idades de 18 a 74 · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT07592689A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Neuro-Behavioral Clinical Research, North Canton
RecrutandoFase 3
Idades de 18 a 74 · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
RecrutandoFase 2
Idades de 18 a 64 · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06547489Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
- Lindner Center of Hope, Mason
RecrutandoFase 1/2
Idades de 18 a 60 · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06795451A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
RecrutandoFase 2
Idades de 18 a 64 · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de jul. de 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Cincinnati
- Clinical Research Site, Cincinnati
RecrutandoFase 3
Idades de 18 a 65 · Todos os sexos · Atualizado em 24 de jul. de 2026 · NCT07484217A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- The Ohio State University Department of Psychiatry, Columbus
RecrutandoFase 2
Idades de 21 a 65 · Todos os sexos · Atualizado em 23 de jul. de 2026 · NCT06820723A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Quest Therapeutics of Avon /ID# 277550, Avon Lake
- OSU Psychiatry Department /ID# 277529, Columbus
RecrutandoFase 2
Idades de 18 a 65 · Todos os sexos · Atualizado em 15 de jun. de 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Ohio State University, Columbus
- Neuro Behavioral Clinical Research, Inc., North Canton
RecrutandoFase 2
Idades de 18 a 65 · Todos os sexos · Atualizado em 11 de mai. de 2026 · NCT06524830Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Cincinnati Childrens Hospital Medical Center, Cincinnati
Recrutando
Idades de 14 a 18 · Todos os sexos · Atualizado em 11 de fev. de 2026 · NCT07217444Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #109, Beachwood
RecrutandoFase 2
Idades de 18 a 65 · Todos os sexos · Atualizado em 20 de jan. de 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de out. de 2025 · NCT06786624Mechanisms of Rumination Change in Adolescent Depression
- Nationwide Children's Hospital, Columbus
- The Ohio State University, Columbus
Recrutando
Idades de 14 a 17 · Todos os sexos · Atualizado em 11 de ago. de 2025 · NCT03859297Study of ALTO-300 in MDD
- Site 202, Cincinnati
RecrutandoFase 2
Idades de 18 a 70 · Todos os sexos · Atualizado em 24 de jul. de 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Cincinnati
RecrutandoFase 4
Idades de 18 a 65 · Todos os sexos · Atualizado em 23 de jan. de 2025 · NCT06223880Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.